Rolando Rodriguez, MD
Endocrinology · Boca Raton, FLNPI 1245344746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations.
Across 440 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$945
- Novo Nordisk$897
- AbbVie$732
- Amgen$592
- Boehringer Ingelheim$471
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,953100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 78 | $1,306 |
| Sanofi-aventis U.S. LLC | 45 | $945 |
| Novo Nordisk | 65 | $897 |
| AbbVie | 41 | $732 |
| Amgen(2 entities) | 31 | $592 |
| Boehringer Ingelheim | 27 | $471 |
| Bayer | 17 | $422 |
| Corcept Therapeutics | 21 | $404 |
| Amneal Pharmaceuticals LLC | 16 | $256 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $203 |
| Radius Health, Inc. | 9 | $150 |
| AstraZeneca(2 entities) | 8 | $149 |
| Xeris Pharmaceuticals, Inc. | 7 | $137 |
| Dexcom, Inc. | 5 | $118 |
| Lifescan, Inc. | 6 | $113 |
| Valeritas, Inc. | 5 | $110 |
| Merck | 6 | $98 |
| Mannkind Corporation | 5 | $91 |
| BD | 4 | $85 |
| Pfizer | 3 | $74 |
| Cvrx, Inc. | 1 | $74 |
| Recordati_rare_diseases_inc. | 4 | $74 |
| Shire North American Group Inc | 3 | $64 |
| IBSA Pharma Inc. | 3 | $63 |
| Abbott | 3 | $57 |
| Novartis | 3 | $54 |
| Johnson & Johnson | 3 | $46 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| EUSA Pharma (US) LLC | 1 | $21 |
| Alvogen Inc | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Vistapharm, Inc. | 1 | $17 |
| Biomerieux Inc | 1 | $15 |
| Medtronic | 1 | $14 |
How this compares
Too few endocrinology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 137 | $199,446 |
| OzempicSemaglutide | 132 | $197,066 |
| TrulicityDulaglutide | 62 | $116,371 |
| JardianceEmpagliflozin | 58 | $70,805 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $60,780 |
| JanuviaSitagliptin Phosphate | 47 | $55,993 |
| SynthroidLevothyroxine Sodium | 328 | $35,071 |
| FarxigaDapagliflozin Propanediol | 30 | $34,967 |
| TradjentaLinagliptin | 22 | $32,484 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 43 | $32,229 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $30,319 |
| EliquisApixaban | 20 | $28,984 |
| RybelsusSemaglutide | 19 | $27,677 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $25,150 |
| WegovySemaglutide | 11 | $21,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humalog Mix 75-25 | $1,306 | $322,933235 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $897 | $246,311162 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $471 | $113,95395 claims |
| MerckJanuvia | $98 | $55,99347 claims |
| AbbVieSynthroid | $732 | $35,071328 claims |
| AstraZenecaFarxiga | $149 | $34,96730 claims |
| PfizerEliquis | $74 | $28,98420 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $945 | $20,38443 claims |
| AmgenProlia | $592 | $19,48411 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $256 | $3,846270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Boca Raton
- Bryan VinikBoca Raton$13K
- Renee FreedmanBoca Raton$10K
- Kathryn JonesBoca Raton$142
- Vivian RoseCoral Springs$14K
- Carlos ZapataTallahassee$5K
- Michael FiliMiami$4K
- Rodolfo Perez LopezHialeah$3K
- Mohammad BaigTampa$2K
- Myat MyintHudson$182
- Alan BalsamDeerfield Beach$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.